blue 🗑 of california

risedronate (ACTONEL)

Diagnoses Considered for Coverage:

- Prevention or Treatment of Postmenopausal Osteoporosis in Women
- Treatment of Osteoporosis in Men
- Prevention or Treatment of Glucocorticoid-Induced Osteoporosis in Men and Women (on continuous systemic glucocorticoid for chronic diseases).

Coverage Criteria:

For generic risedronate:

- For diagnoses listed above, and
- Inadequate response or intolerable side effect with alendronate (Fosamax) and ibandronate (Boniva), and
- Dose does not exceed FDA approved dosing.

For brand-name Actonel:

- Meets above coverage criteria for generic risedronate, and
- Allergic or intolerable side effect to the generic formulation.

Coverage Duration: Length of benefit

Effective: 6/18/2015